PHILADELPHIA, Nov. 28, 2016 /PRNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced today that is has successfully completed animal trials. The company is harnessing the power of the immune system to target a specific protein, MAGE A, in an effort to find a better cure for triple negative breast cancer. During animal trials, the company tested the same four goals they had set with in vitro studies. The research indicated that their vector expressed the protein and that the protein got an immune response. ImMAGE also determined through animal trials that the company had created the right immune cells to kill the targeted cancer cells in vitro. The next step would be conduct the efficacy experiments in vivo. "The results of our in vitro trials have been promising and I am excited about the potential to transform our research into a tangible treatment," ImMAGE President and COO Mahesh Narayanan said, "We are just finishing up our qualitative and quantitative analysis of the animal studies at the moment in preparation for our first pre-IND meeting with the FDA in December." With a quicker timeline than projected, ImMAGE plans to file for the FDA's IND program for approval into Phase 1 human trials in late 2017. The company is also beginning to raise another round of funding in order to continue R&D efforts. About ImMAGE Biotherapeutics ImMAGE Biotherapeutics Corp. (OTCMKTS: IMMG) was founded in 2015 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.immagebio.com.